Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in
adults. As supplements to standard of care (SOC), various immunotherapies improve the …

Tumors can be classified into distinct immunophenotypes based on the presence and
arrangement of cytotoxic immune cells within the tumor microenvironment (TME). Hot …

Total tumor clearance through immunotherapy is associated with a fully coordinated innate
and adaptive immune response, but knowledge on the exact contribution of each immune …

Immune checkpoints (ICPs) can promote tumor growth and prevent immunity‐induced
cancer cell apoptosis. Fortunately, targeting ICPs, such as programmed cell death 1 (PD‐1) …

Low-expression antigens, especially neoantigens, pose a significant challenge in
immunotherapy for low immunogenicity pancreatic cancer. Increasing the tumor mutation …

We recently developed an immuno-oncotherapy against human papillomavirus (HPV)-
induced tumors based on a lentiviral vector encoding the Early E6 and E7 oncoproteins of …

Highlights Butyrate could suppress IFN-γ-induced PD-L1 up-regulation in Colorectal Cancer
(CRC) cells. Butyrate promoted the lysine acetylation of STAT1 to reduce STAT1 expression …

Immune checkpoint therapies (ICT) for advanced solid tumors mark a new milestone in
cancer therapy. Yet their efficacy is often limited by poor immunogenicity, attributed to …

Use of immune checkpoint inhibitors (ICIs) as cancer immunotherapy has advanced rapidly
in the clinic. We recently reported that tumor stroma-derived angiopoietin-like protein 2 …

Because cancer cells have a genetically unstable nature, they give rise to genetically
different variant subclones inside a single tumor. Understanding cancer heterogeneity and …